Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.

Although the increase in median survival did not reach statistical significance, this result is of considerable interest as it stands in contrast to what we observed previously in this same model using sunitinib and paclitaxel, which is recapitulated in Fig. 3b [ 74 ], where the combination treatment had a minor effect on survival.

also in 111,027 other papers